NCT02936206View on ClinicalTrials.gov

Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.

PHASE1TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

May 1, 2020

Study Completion Date

May 1, 2020

Conditions
Breast Cancer
Interventions
DRUG

Fulvestrant

fulvestrant 750 mg (three 5 ml injections slowly over 1-2 mn per injection in the buttocks) on day 1 only

DRUG

Tamoxifen

14 days of treatment with tamoxifen 20mg orally each day

Trial Locations (3)

10019

Mount Sinai West, New York

10025

Mount Sinai St. Luke's, New York

10029

Icahn School of Medicine at Mount Sinai, New York

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Icahn School of Medicine at Mount Sinai

OTHER